A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury
NCT ID: NCT06888115
Last Updated: 2025-07-11
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
24 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-03-13
Study Completion Date
2025-06-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Phase I Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159
NCT05082779
Primary Sclerosing Cholangitis (PSC)
COMPLETED
PHASE1
Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Mild, Moderate and Normal Hepatic Impairment
NCT06671509
Insomnia
Hepatic Impairment
COMPLETED
PHASE1
Pharmacokinetics of ZSP1273 in Participants With Hepatic Impairment
NCT05856513
Hepatic Impairment
Pharmacokinetics
COMPLETED
PHASE1
A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement
NCT06985615
Hepatic Impairment
Healthy Volunteers
RECRUITING
PHASE1
A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod
NCT04639115
Liver Diseases
Digestive System Diseases
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To evaluate the PK characteristics of CS0159 in subjects with mild hepatic impairment (Child-Pugh Class A), moderate hepatic impairment (Child-Pugh Class B), and sex, age, and body weight-matched healthy subjects with normal hepatic function, so as to provide a scientific basis for the appropriate dose and/or dosing interval adjustment in subjects with hepatic impairment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Primary Biliary Cholangitis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Guoup 1
Single oral dose of CS0159 in subjects with Child-Pugh Grade A
Group Type
EXPERIMENTAL
CS0159
Intervention Type
DRUG
Single oral dose of CS0159 4mg
Guoup 2
Single oral dose of CS0159 in subjects with Child-Pugh Grade B
Group Type
EXPERIMENTAL
CS0159
Intervention Type
DRUG
Single oral dose of CS0159 4mg
Guoup 3
Single oral dose of CS0159 in healthy subjects with normal liver function
Group Type
EXPERIMENTAL
CS0159
Intervention Type
DRUG
Single oral dose of CS0159 4mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CS0159
Single oral dose of CS0159 4mg
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Subjects who fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial and sign a written informed consent form, and are able to complete the entire trial process according to the trial requirements.
2. Subjects aged 18 to 75 years (inclusive) at the time of signing the informed consent form; male or female.
3. At screening, the weight of male subjects is ≥50 kg, the weight of female subjects is ≥45 kg, and both are ≤100 kg; body mass index \[BMI = weight (kg)/height2 (m2)\] is within 18.0-32.0 kg/m2 (inclusive).
4. Subjects and their partners agree to have no plans for conception or sperm/egg donation from the signing of the informed consent until 6 months after the last dosing of the study drug and voluntarily take effective contraception measures.
1. Group 1: subjects with mild hepatic impairment (Child-Pugh Class A, score 5-6), see Appendix 1 for specific scoring.
2. Group 2: subjects with moderate hepatic impairment (Child-Pugh Class B, score 7-9), see Appendix 1 for specific scoring.
3. Subjects with hepatic impairment caused by prior primary liver disorders, who have not used albumin within 14 days prior to screening, and have been diagnosed with stable (≥1 month) hepatic impairment through past medical history, physical examination, laboratory tests, or imaging examinations.
4. Subjects who have not taken any medications within 4 weeks prior to screening, or, for those requiring long-term treatment for hepatic impairment and/or other comorbid diseases, have been on stable medication for at least 4 weeks (stable medication is determined by the investigator, excluding medications prohibited by the protocol).
2. Subjects aged 18 to 75 years (inclusive) at the time of signing the informed consent form; male or female.
3. At screening, the weight of male subjects is ≥50 kg, the weight of female subjects is ≥45 kg, and both are ≤100 kg; body mass index \[BMI = weight (kg)/height2 (m2)\] is within 18.0-32.0 kg/m2 (inclusive).
4. Subjects and their partners agree to have no plans for conception or sperm/egg donation from the signing of the informed consent until 6 months after the last dosing of the study drug and voluntarily take effective contraception measures.
1. Group 1: subjects with mild hepatic impairment (Child-Pugh Class A, score 5-6), see Appendix 1 for specific scoring.
2. Group 2: subjects with moderate hepatic impairment (Child-Pugh Class B, score 7-9), see Appendix 1 for specific scoring.
3. Subjects with hepatic impairment caused by prior primary liver disorders, who have not used albumin within 14 days prior to screening, and have been diagnosed with stable (≥1 month) hepatic impairment through past medical history, physical examination, laboratory tests, or imaging examinations.
4. Subjects who have not taken any medications within 4 weeks prior to screening, or, for those requiring long-term treatment for hepatic impairment and/or other comorbid diseases, have been on stable medication for at least 4 weeks (stable medication is determined by the investigator, excluding medications prohibited by the protocol).
Exclusion Criteria
1. Subjects known to have a history of allergy to components or excipients of the investigational product, those with an allergic constitution (multiple drug and food allergies), or those with a history of allergic diseases (such as asthma, urticaria, eczema dermatitis, etc.).
2. Subjects who have a malignant tumor, or a history of malignant tumor regardless of time from diagnosis.
3. Subjects with severe infection, trauma, intestinal operation, or other major surgery within 4 weeks prior to screening.
4. Subjects with a history of organic heart disease, cardiac failure, myocardial infarction, angina pectoris, unexplained arrhythmia, torsades de pointes, ventricular tachycardia, or long QT syndrome, or who have symptoms and family history of long QT syndrome (indicated by genetic evidence or sudden death of a close relative at a young age due to cardiac causes).
5. Subjects who have or previously had arrhythmia that requires clinical intervention and may affect survival during the trial; or those with clinically significant electrocardiogram abnormalities at screening \[such as tachycardia/bradycardia requiring drug therapy, second- to third-degree atrioventricular block, or prolonged QTcF interval (male QTcF \> 450 ms, female QTcF \> 470 ms) (corrected using Fridericia's formula), or other clinically significant abnormalities determined by the clinician\].
6. Serum creatinine \> upper limit of normal (ULN), or estimated glomerular filtration rate (eGFR) calculated using the modification of diet in renal disease (MDRD) formula ˂60 mL/min/1.73 m2.
7. Subjects who are scheduled for surgery or are likely to require hospitalization during the study period.
8. Subjects with blood pressure ≥140/90 mmHg (allow retesting 2 times).
9. Subjects with resting heart rate \>100 bpm (allow retesting 2 times).
10. Subjects positive for HIV antibody (HIV-Ab) testing.
11. Within 4 weeks prior to drug dosing, subjects who have used herbal medicines or any drugs that may affect CYP3A enzyme activity (such as CYP3A inducers, i.e., barbiturates, carbamazepine, glucocorticoids, etc.; inhibitors, i.e., SSRI antidepressants, cimetidine, diltiazem, macrolides, nitroimidazoles, etc.).
12. Subjects who have taken any medications (including herbal medicines, vitamins, and health supplements) within 14 days before dosing (or 5 half-lives, whichever is longer), except for stable medications in subjects with hepatic impairment.
13. Subjects who have participated in other clinical trials and received investigational products or medical devices within 1 month prior to screening, using the date of the last dosing in the clinical study as the time reference (if the clinical study drug has a long half-life, at least 5 half-lives must have elapsed between dosing in that study and dosing in this study).
14. Subjects who have experienced blood loss or blood donation of ≥400 mL within 3 months prior to dosing, or plan to donate blood within 1 month after the end of this trial.
15. Subjects who are addicted to smoking, or smoked more than 5 cigarettes per day within 3 months prior to screening, or unable to stop any tobacco product use during the study period.
16. At present or within 1 month prior to screening, subjects with regular alcohol use, that is, women who consume more than 7 units of alcohol per week, men who consume more than 14 units of alcohol per week (1 unit = 14 g of pure alcohol); or subjects who test positive for alcohol breath at baseline; or who are unable to abstain from alcohol during the study.
17. Subjects with drug abuse or use of soft drugs (e.g., marijuana) within 3 months prior to dosing, or use of hard drugs (e.g., cocaine, amphetamines, phencyclidine, etc.) within 1 year prior to dosing, or positive baseline urine drug abuse screening.
18. Subjects who have consumed foods or beverages containing grapefruit juice/pomelo juice, or containing methylxanthine purines (tea, coffee, cola, chocolate, and energy drinks) within 48 h before dosing, or other factors affecting drug absorption, distribution, metabolism, excretion, etc.
19. Subjects who cannot tolerate venipuncture or have a fear of needles or blood.
20. Subjects who have received a vaccine injection within 1 month prior to screening.
21. Pregnant or breastfeeding women, or those with a positive blood pregnancy test.
22. Subjects who, in the investigator's opinion, have poor compliance or other factors making them unsuitable for participation in this trial.
1. Subjects with positive syphilis tests.
2. Subjects with a history of liver transplant.
3. Subjects with drug-induced liver injury.
4. Subjects with acute liver injury due to various causes.
5. Subjects with cholestatic liver disease.
6. Imaging indicates the presence of hepatocellular carcinoma (HCC) lesions and/or alpha-fetoprotein \>20 ng/mL.
7. At screening, serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 5× ULN.
8. Subjects with hepatic failure and/or advanced hepatic decompensation as evidenced by:
1. hepatic encephalopathy grade ≥3,
2. ascites grade ≥2, and/or
3. portal hypertension ≥10 mmHg.
9. Apart from the primary liver disease itself, subjects with any history of serious diseases, or with a medical history or clinically significant abnormal laboratory test that the investigator believes may affect the study results, including but not limited to a history of diseases of the circulatory system, endocrine system, nervous system, digestive system, urinary system, or blood, immune, psychiatric, and metabolic diseases.
1. Subjects positive for treponema pallidum (TP) antibody test.
2. Subjects with previous primary diseases of major organs, including but not limited to neurological/psychiatric, cardiovascular, gastrointestinal, respiratory, urinary, endocrine, hematological, immune, and other diseases, whom the investigator determines are unsuitable to participate in this trial.
3. Subjects with a history of hepatic dysfunction, or those whose results from various examinations during screening (including physical examination, vital signs, hematology, urinalysis, blood chemistry, coagulation function, thyroid function, 12-lead electrocardiogram, chest PA X-ray, abdominal ultrasound, etc.) are judged by the investigator to be abnormal and of clinical significance.
4. Subjects with an age not within ±10 years of the mean age of subjects with moderate and mild hepatic impairment, and/or weight not within ±10% of the mean weight of subjects with moderate and mild hepatic impairment.
5. Subjects with past or current hepatitis B and/or hepatitis C.
2. Subjects who have a malignant tumor, or a history of malignant tumor regardless of time from diagnosis.
3. Subjects with severe infection, trauma, intestinal operation, or other major surgery within 4 weeks prior to screening.
4. Subjects with a history of organic heart disease, cardiac failure, myocardial infarction, angina pectoris, unexplained arrhythmia, torsades de pointes, ventricular tachycardia, or long QT syndrome, or who have symptoms and family history of long QT syndrome (indicated by genetic evidence or sudden death of a close relative at a young age due to cardiac causes).
5. Subjects who have or previously had arrhythmia that requires clinical intervention and may affect survival during the trial; or those with clinically significant electrocardiogram abnormalities at screening \[such as tachycardia/bradycardia requiring drug therapy, second- to third-degree atrioventricular block, or prolonged QTcF interval (male QTcF \> 450 ms, female QTcF \> 470 ms) (corrected using Fridericia's formula), or other clinically significant abnormalities determined by the clinician\].
6. Serum creatinine \> upper limit of normal (ULN), or estimated glomerular filtration rate (eGFR) calculated using the modification of diet in renal disease (MDRD) formula ˂60 mL/min/1.73 m2.
7. Subjects who are scheduled for surgery or are likely to require hospitalization during the study period.
8. Subjects with blood pressure ≥140/90 mmHg (allow retesting 2 times).
9. Subjects with resting heart rate \>100 bpm (allow retesting 2 times).
10. Subjects positive for HIV antibody (HIV-Ab) testing.
11. Within 4 weeks prior to drug dosing, subjects who have used herbal medicines or any drugs that may affect CYP3A enzyme activity (such as CYP3A inducers, i.e., barbiturates, carbamazepine, glucocorticoids, etc.; inhibitors, i.e., SSRI antidepressants, cimetidine, diltiazem, macrolides, nitroimidazoles, etc.).
12. Subjects who have taken any medications (including herbal medicines, vitamins, and health supplements) within 14 days before dosing (or 5 half-lives, whichever is longer), except for stable medications in subjects with hepatic impairment.
13. Subjects who have participated in other clinical trials and received investigational products or medical devices within 1 month prior to screening, using the date of the last dosing in the clinical study as the time reference (if the clinical study drug has a long half-life, at least 5 half-lives must have elapsed between dosing in that study and dosing in this study).
14. Subjects who have experienced blood loss or blood donation of ≥400 mL within 3 months prior to dosing, or plan to donate blood within 1 month after the end of this trial.
15. Subjects who are addicted to smoking, or smoked more than 5 cigarettes per day within 3 months prior to screening, or unable to stop any tobacco product use during the study period.
16. At present or within 1 month prior to screening, subjects with regular alcohol use, that is, women who consume more than 7 units of alcohol per week, men who consume more than 14 units of alcohol per week (1 unit = 14 g of pure alcohol); or subjects who test positive for alcohol breath at baseline; or who are unable to abstain from alcohol during the study.
17. Subjects with drug abuse or use of soft drugs (e.g., marijuana) within 3 months prior to dosing, or use of hard drugs (e.g., cocaine, amphetamines, phencyclidine, etc.) within 1 year prior to dosing, or positive baseline urine drug abuse screening.
18. Subjects who have consumed foods or beverages containing grapefruit juice/pomelo juice, or containing methylxanthine purines (tea, coffee, cola, chocolate, and energy drinks) within 48 h before dosing, or other factors affecting drug absorption, distribution, metabolism, excretion, etc.
19. Subjects who cannot tolerate venipuncture or have a fear of needles or blood.
20. Subjects who have received a vaccine injection within 1 month prior to screening.
21. Pregnant or breastfeeding women, or those with a positive blood pregnancy test.
22. Subjects who, in the investigator's opinion, have poor compliance or other factors making them unsuitable for participation in this trial.
1. Subjects with positive syphilis tests.
2. Subjects with a history of liver transplant.
3. Subjects with drug-induced liver injury.
4. Subjects with acute liver injury due to various causes.
5. Subjects with cholestatic liver disease.
6. Imaging indicates the presence of hepatocellular carcinoma (HCC) lesions and/or alpha-fetoprotein \>20 ng/mL.
7. At screening, serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 5× ULN.
8. Subjects with hepatic failure and/or advanced hepatic decompensation as evidenced by:
1. hepatic encephalopathy grade ≥3,
2. ascites grade ≥2, and/or
3. portal hypertension ≥10 mmHg.
9. Apart from the primary liver disease itself, subjects with any history of serious diseases, or with a medical history or clinically significant abnormal laboratory test that the investigator believes may affect the study results, including but not limited to a history of diseases of the circulatory system, endocrine system, nervous system, digestive system, urinary system, or blood, immune, psychiatric, and metabolic diseases.
1. Subjects positive for treponema pallidum (TP) antibody test.
2. Subjects with previous primary diseases of major organs, including but not limited to neurological/psychiatric, cardiovascular, gastrointestinal, respiratory, urinary, endocrine, hematological, immune, and other diseases, whom the investigator determines are unsuitable to participate in this trial.
3. Subjects with a history of hepatic dysfunction, or those whose results from various examinations during screening (including physical examination, vital signs, hematology, urinalysis, blood chemistry, coagulation function, thyroid function, 12-lead electrocardiogram, chest PA X-ray, abdominal ultrasound, etc.) are judged by the investigator to be abnormal and of clinical significance.
4. Subjects with an age not within ±10 years of the mean age of subjects with moderate and mild hepatic impairment, and/or weight not within ±10% of the mean weight of subjects with moderate and mild hepatic impairment.
5. Subjects with past or current hepatitis B and/or hepatitis C.
Minimum Eligible Age
18 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cascade Pharmaceuticals, Inc
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhao wei feng, Master
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of Soochow University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Site Status
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Site Status
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Site Status
Countries
Review the countries where the study has at least one active or historical site.
China
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CS0159-HI-CN-I-05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function
NCT04116476
COMPLETED
PHASE1
Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment
NCT04293029
COMPLETED
PHASE1
A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function
NCT01516047
COMPLETED
PHASE1
Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function
NCT04993404
COMPLETED
PHASE1
Pharmacokinetic Study of CXB909 in Healthy Male Subjects
NCT01505907
UNKNOWN
PHASE1/PHASE2
KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment
NCT04166942
COMPLETED
PHASE1
Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic Impairment
NCT06674915
COMPLETED
PHASE1
Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects
NCT05391724
COMPLETED
PHASE1
Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones
NCT00576589
COMPLETED
PHASE1
Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment
NCT04791553
COMPLETED
PHASE1
Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
NCT04091061
COMPLETED
PHASE1
GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers
NCT05814926
COMPLETED
PHASE1
Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of UCB5857 in Healthy Subjects
NCT02207595
COMPLETED
PHASE1
Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis
NCT01359462
COMPLETED
PHASE1
A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic Impairment
NCT05376839
TERMINATED
PHASE1
Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic Function
NCT05283915
COMPLETED
PHASE1
Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment
NCT05599932
COMPLETED
PHASE1
Pharmacokinetics of BAF312 in Patients With Hepatic Impairment
NCT01565902
COMPLETED
PHASE1
Pharmacokinetic Characteristics of Subjects with Hepatic Insufficiency and Healthy Subjects
NCT05711797
COMPLETED
PHASE1
Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment
NCT03289234
COMPLETED
PHASE1
Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment
NCT05751759
COMPLETED
PHASE1
A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function
NCT06390410
COMPLETED
PHASE1
Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants
NCT04991571
COMPLETED
PHASE1
Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control Subjects
NCT05373953
COMPLETED
PHASE1
Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment
NCT02873650
TERMINATED
PHASE1